End-of-day quote
Shanghai S.E.
03:30:00 24/05/2024 am IST
5-day change
1st Jan Change
27.02
CNY
+0.07%
-4.35%
-16.19%
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. announces an Equity Buyback for 3,600,000 shares, for CNY 216 million.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHSE:603896) commences share repurchases on October 13, 2020, under the program mandated by the shareholders in the Extraordinary General Meeting held on October 13, 2020. As per the mandate, the company is authorized to repurchase up to 3,600,000 shares for a maximum amount of CNY 216 million. The shares will be repurchased at price not more than CNY 60 per share. All shares to be repurchased will be used to implement equity incentives. The program will be valid for twelve months from the date of approval.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
25/04
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
26/23/26
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.(XSSC:603896) added to S&P Global BMI Index
18/23/18
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million.
13/23/13
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
26/23/26
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
27/23/27
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
03/23/03
CI
Shouxiangu Pharma Unit Secures Re-Registration Approval for Three Drugs
17/23/17
MT
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
26/22/26
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
21/22/21
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
28/22/28
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
27/22/27
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
27/21/27
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
13/21/13
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 4, 2020, has expired with 3,585,000 shares, representing 2.5% for CNY 165.08 million.
11/21/11
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
08/21/08
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
24/21/24
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
02/21/02
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
28/21/28
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
02/21/02
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
31/21/31
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
05/21/05
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. announces an Equity Buyback for 3,600,000 shares, for CNY 216 million.
04/20/04
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
27/20/27
CI
Xu Meiyun completed the acquisition of 5.99% stake in Zhejiang Shouxiangu Pharmaceutical Co., Ltd. from Zhejiang Shouxiangu Investment Management Co., Ltd.
13/20/13
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a China-based company principally engaged in the breeding, cultivation, processing and sales of traditional Chinese medicinal materials, such as the ganoderma lucidums and dendrobium officinales. The Company's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The Company mainly operates its businesses in domestic markets through wholesaling and direct sales.
More about the company
1st Jan change
Capi.
-16.19% 739M +37.65% 6.11B -19.68% 4.33B +4.49% 3.22B -15.69% 2.96B -5.64% 2.42B +44.89% 1.92B -12.71% 1.61B -4.27% 1.57B -14.86% 1.51B
Alternative Medicine
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1